RxDoctor Payments DataLook up a doctor →

Justin Mann, MD

Interventional Pain Medicine · Jacksonville, FLNPI 1790075703

Payments from drug & device makers

$243,124in general payments, 2019–2025

Across 619 payments — averaging $392.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$237K
  • Kowa Pharmaceuticals America, Inc.$1K
  • Abbott$1K
  • Amgen$392
  • Radius Health, Inc.$322
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$303
  • plus $2K from 33 others

What the payments were for

  • Consulting fees$2,2551%
  • Speaking & faculty fees$203,46484%
  • Travel & lodging$23,12810%
  • Food & beverage$14,1856%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$243,124 in reported general payments places this provider in the 90th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$218,523
Medicare patients
266
Services billed
2,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,034$32,771
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen998$24,730
Pregabalin731$15,698
LyricaPregabalin18$11,172
Oxycodone Hcl252$3,389
Fentanyl25$2,348
Tramadol Hcl312$2,212
Gabapentin99$1,125
Diclofenac Sodium20$826
Acetaminophen-CodeineAcetaminophen With Codeine39$772
Morphine Sulfate ErMorphine Sulfate34$756
Methocarbamol37$648
Tizanidine Hcl53$549
Hydromorphone Hcl24$492
Methadone Hcl22$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$27$11,17218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →